A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients with Advanced, Refractory or Recurrent Solid Tumors
NCT #
not yet registered
Condition(s)
Breast Cancer, Solid Tumor
Molecular Target(s)
CMTR2
Drug Classification(s)
Molecular Targeted Therapy, Small Molecule (Targeted)
Agents(s)
AT-1965
Phase(s)
I/II
Mechanism of Action
AT-1965 is a CMTR2 inhibitor
Purpose
- This study is being done to find out if a new investigational drug, AT-1965, is safe when given to you.
- It aims to assess the pharmacokinetics (PK) to measure how your body takes up, breaks down, and clears AT-1965.
- Additionally, it will evaluate the Pharmacodynamics (PD) to show how your body responds to the drug.
- The study also aims to analyze the antitumor activity to measure how AT-1965 works in your tumors.
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Molecular Targeted Therapy, Trispecific Antibodies
ROR1
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
Yes
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.